期刊文献+

甲亢患者碘治疗后^(131)I滞留量与周围剂量当量率的关系 被引量:1

Study on retained body activity and external dose rate of patients receiving ^(131)I therapy for hyperthyroidism
下载PDF
导出
摘要 为实现通过测量患者周围剂量当量率间接估算出其体内131I活度滞留量,建立了甲亢患者体内131I滞留量与周围剂量当量率的关系函数。选取68例甲亢患者,测量患者服碘后0.5 h、4 h、8 h、24 h、48 h、72 h、96 h、120 h、144 h和192 h时距离患者0.3 m、0.6 m、1 m和2 m处的周围剂量当量率;同时收集患者服碘后上述各时间段的全部尿液,测量患者尿液中131I放射性活度,估算出患者的体内131I活度滞留量。拟合得到患者体内131I活度滞留量(Y,单位MBq)与1 m处周围剂量当量率(X,单位μSv/h)的关系为函数Y=22.8X+3.3。医护人员可以通过测量患者1 m处的周围剂量当量率估算出患者的体内131I活度滞留量,该法方便快捷,能够极大降低周围人群的受照剂量,从而对医护人员进行有效的防护。 This study established the function of the retained body activity and the external dose rate of patients treated by 131I. The retained body activities of patients can be estimated by the external dose rate based on this function. The external dose rate and retained body activity of sixty-eight patients were measured. The external dose rate was measured at 0.5 h, 4 h, 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 144 h and 192 h after the administration with distances of 0.3 m, 0.6 m, 1 m, and 2 m, respectively, with the urine received at the same time for the calculation of the retained body activity. The function of them is Y=22.8X+3.3; Y stands for the retained body activity (MBq), X stands for the external dose rate of patient at lm (μSv/h). This study is beneficial for radiation safety decision-making.
出处 《辐射研究与辐射工艺学报》 CAS CSCD 2015年第5期20-24,共5页 Journal of Radiation Research and Radiation Processing
基金 中国医学科学院放射医学研究所青年探索基金项目(1556-1)资助
关键词 甲亢 131I 活度滞留量 尿液 周围剂量当量率 Hyperthyroidism, 131I, Retained body activity, Urine, External dose rate
  • 相关文献

参考文献15

  • 1Arielle J E, Robert A. Practice guideline for the detection and management of thyroid dysfunction-A comparative review of the recommendations [J]. Clinical Endocrinology, 1999, 51(1): 11-18. DOI: 10.1046/j.1365- 2265.1999.00797.x.
  • 2陆克义,李险峰.甲状腺疾病患者^(131)I治疗后对他人的辐射危害评价[J].国外医学(放射医学核医学分册),2004,28(5):226-229. 被引量:9
  • 3孙作忠,宁尚义,张丹枫.碘-131治疗甲状腺疾病的辐射防护问题[J].中国辐射卫生,2005,14(3):203-203. 被引量:16
  • 4蒋宁一,林岩松,关海霞,谭建,李林,高再荣,陆汉魁,吴艺捷,管樑,袁卫红,金刚,包建东,黄钢.^(131)I治疗格雷夫斯甲亢指南(2013版)[J].标记免疫分析与临床,2014,21(1):92-104. 被引量:47
  • 5Cui S, Jiao L, Tan J, et al. Estimating radiation absorbed dose of individuals nearby 131I-treated hyperthyroid patients [J]. Health Physics, 2014, 106(3): 365-9. DOI: 10.1097/HP.0b013e3182alc8d5.
  • 6Mohammadi H. Radiation exposure rate from 131I-treated hyperthyroid patients-a dynamic study, with data for up to 42 d post therapy [J]i Health physics, 2005, 88(5): 486-90.
  • 7A1-Haj A N, Lagarde C S, Lobriguito A M. Patient parameters and other radiation safety issues in 1311 therapy for thyroid cancer treatment [J]. Health Physics, 2007, 93: 656-66.
  • 8核工业标准化研究所.GB18871-2002电离辐射防护与辐射源安全基本标准[S].北京:中国标准出版社,2002-10-08.
  • 9张永学,黄钢.核医学[M].北京:人民卫生出版社,2010.
  • 10ICRP Publication 94, Release of patients after therapy with unsealed radionuclides [M]. Oxford, UK: Pergamon Press, 2004.

二级参考文献86

  • 1王勤奋,张承刚,赵晓斌,施龙宝.1003例Graves病^(131)I治疗临床分析[J].中华核医学杂志,2005,25(2):108-110. 被引量:62
  • 2周振虎,贾晓春,杜玉洁,杨金兰.~131Ⅰ治疗Graves病合并周期性麻痹的疗效分析[J].中华核医学杂志,2006,26(5):314-314. 被引量:16
  • 3中华人民共和国国务院.医疗事故处理条例[Z].,2002年4月4日第351号令..
  • 4中华人民共和国侵权责任法.2010-07-01.
  • 5Vetter RJ. Regulations for radioiodine therapy in the United States:current status and the process of change[J]. Thyroid, 1997, 7(2):209-211.
  • 6US Nuclear Regulatory Commission. 10 CFR Part 35.75: Release of individuals containing unsealed byproduct material or implants conaining byproduct material[R]. Washington, DC: US Government Printing Office, 2000.
  • 7US Nuclear Regulatory Commission. Regulatory Guide 8.39: Release of patients administered radioactive materials[R]. Washington, DC:NRC, 1997.
  • 8Coover LR, Silberstein EB, Kuhn PJ, et al. Therapeutic 131I in outpa tients: a simplified method conforming to the Code of Federal Regulations, title 10, part 35.75[J]. J Nucl Med, 2000, 41(11): 1868-1875.
  • 9Council of the European Union. Guideline 96/29/EURATOM to determine basic directions for public and workers against ionizing radiation related dangers[R]. Official Journal of the European Communities, 1996, L159: 1-28.
  • 10Hertz S, Robert A. Application of radioactive iodine in therapy of Graves disease[J]. J Clin Invest, 1942, 21: 624.

共引文献88

同被引文献8

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部